Fubotv earnings beat by $0.10, revenue topped estimates
WHITE BEAR LAKE, Minnesota - Envoy Medical Inc. (NASDAQ:COCH), a $31.5 million market cap medical device company currently trading at $1.48 per share, has been granted two new U.S. patents for its implantable hearing technology, the company announced Tuesday. According to InvestingPro analysis, the stock appears undervalued despite showing significant price volatility with a beta of 2.2.
The patents, both issued on June 3, 2025, relate to the company’s fully implanted hearing solutions. U.S. Patent No. 12,318,607 covers methods for compensating for variability in middle ear sensors through filtering techniques. U.S. Patent No. 12,318,613 involves using external devices to designate and analyze signals within fully implantable cochlear implant systems.
"We believe these recent patent issuances further demonstrate our team’s ability to innovate and push boundaries in hearing health," said Brent Lucas, CEO of Envoy Medical, in a press release statement. While the company continues to advance its technology, InvestingPro data reveals challenges in financial performance, with negative gross margins and accelerated cash burn. InvestingPro subscribers have access to over 7 additional key insights about COCH’s financial health.
Envoy Medical develops fully implanted hearing technologies designed to eliminate external components by leveraging the natural anatomy of the ear for sound detection. The company’s product portfolio includes the Esteem fully implanted active middle ear implant, which has been commercially available in the U.S. since 2010, and the investigational Acclaim cochlear implant.
The Acclaim cochlear implant received Breakthrough Device Designation from the U.S. Food and Drug Administration in 2019 and remains under investigation. The device is intended to address severe to profound sensorineural hearing loss in adult patients deemed appropriate candidates by qualified physicians. Analysts maintain optimistic price targets ranging from $5 to $9.50, with the company’s next earnings report scheduled for July 31, 2025.
The Esteem implant is currently FDA-approved for adults diagnosed with moderate to severe sensorineural hearing loss, providing 24/7 hearing capability without external components.
In other recent news, Envoy Medical has drawn the remaining $5 million available under a promissory note with GAT Funding, LLC. As part of this transaction, GAT Funding received a warrant to purchase 750,000 shares of Envoy Medical’s Class A Common Stock at an exercise price of $1.48 per share. Additionally, the company has appointed Robert Potashnick as interim Chief Financial Officer. Potashnick will serve on a fractional consultant basis through a consulting agreement with Oasis Business Consulting LLC.
Envoy Medical also disclosed the departure of its former CFO, David R. Wells, with the company’s CEO, Brent T. Lucas, temporarily assuming CFO responsibilities. In a significant development, Envoy Medical announced the successful activation of its Acclaim® cochlear implant in all 10 participants of its clinical trial’s initial phase. The Acclaim CI has received Breakthrough Device Designation from the FDA and is designed for those with severe sensorineural hearing loss.
The company has scheduled its Annual Meeting of Stockholders for May 28, 2025, in Vadnais Heights, Minnesota. Shareholders of record as of April 8, 2025, will be eligible to vote. Envoy Medical’s recent activities reflect its ongoing efforts in both financial and clinical advancements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.